CCL19 and central nervous system cancer: In the Gusu in‐house dataset consisting of 24 patients with glioma, TRAF3IP3, TNFAIP3, ICOSLG, IL11, and PTGES, showed a trend of increasing expression with increasing tumor grade, whereas CCL19 was not (Figure S3C, Supporting Information).